Get the Stockscreener App
94.60
0.90%
-0.86
Pre-market:
94.00
-0.60
-0.63%
Axsome Therapeutics Inc stock is traded at $94.60, with a volume of 363.68K.
It is down -0.90% in the last 24 hours and up +1.34% over the past month.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$95.46
Open:
$94.82
24h Volume:
363.68K
Relative Volume:
0.81
Market Cap:
$4.49B
Revenue:
$291.49M
Net Income/Loss:
$-308.55M
P/E Ratio:
-20.88
EPS:
-4.53
Net Cash Flow:
$-168.02M
1W Performance:
-3.30%
1M Performance:
+1.34%
6M Performance:
+21.94%
1Y Performance:
+57.56%
1-Day Range:
$94.24
$96.92
1-Week Range:
$90.86
$99.67
52-Week Range:
$58.61
$105.00
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Name
Axsome Therapeutics Inc
Sector
Industry
Phone
(212) 332-3241
Address
ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK
Compare AXSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| AXSM | 94.60 | 4.49B | 291.49M | -308.55M | -168.02M | -4.53 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-24 | Initiated | Wells Fargo | Overweight |
| Aug-06-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Apr-29-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Jan-25-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Aug-08-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-05-23 | Initiated | Piper Sandler | Neutral |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Sep-07-22 | Resumed | Mizuho | Buy |
| Aug-10-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-10-21 | Initiated | Berenberg | Buy |
| Jan-08-21 | Initiated | Jefferies | Buy |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Sep-29-20 | Initiated | BofA Securities | Underperform |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-14-20 | Initiated | Cowen | Outperform |
| Dec-30-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-17-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-19 | Reiterated | Guggenheim | Buy |
| Oct-16-19 | Initiated | Guggenheim | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-28-19 | Initiated | SunTrust | Buy |
| May-23-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-08-19 | Initiated | SVB Leerink | Outperform |
| Mar-15-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Dec-15-15 | Initiated | Cantor Fitzgerald | Buy |
| Dec-14-15 | Initiated | Ladenburg Thalmann | Buy |
View All
Axsome Therapeutics Inc Stock (AXSM) Latest News
Axsome Therapeutics (NASDAQ:AXSM) Rating Increased to Hold at StockNews.com - MarketBeat
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up - MSN
Royce & Associates LP Has $2.02 Million Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
First Turn Management LLC Trims Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Is It Too Late to Buy Viking Therapeutics Stock? - The Motley Fool
FY2024 EPS Estimates for AXSM Increased by Leerink Partnrs - MarketBeat
Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript - AOL
Axsome Therapeutics Inc (AXSM) Quarterly 10-Q Report - Quartzy
Axsome Advances Sleep Disorder Pipeline as Sunosi Prescriptions Increase in Q3 - Sleep Review
Equities Analysts Offer Predictions for AXSM FY2027 Earnings - MarketBeat
William Blair Issues Pessimistic Outlook for AXSM Earnings - MarketBeat
Axsome stock price target increased, rating held on strong sales - Investing.com
Axsome stock price target increased, rating held on strong sales By Investing.com - Investing.com UK
Axsome Therapeutics stock hits 52-week high at $98.61 By Investing.com - Investing.com Nigeria
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2024 Earnings Call Transcript - Insider Monkey
Robert W. Baird Raises Axsome Therapeutics (NASDAQ:AXSM) Price Target to $116.00 - MarketBeat
Earnings call: Axsome Therapeutics reports record quarterly revenue By Investing.com - Investing.com Australia
Versor Investments LP Acquires New Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics’ Strong Q3 Growth Amidst Strategic Expansions - TipRanks
Axsome: Q3 Earnings Snapshot - Houston Chronicle
Earnings call: Axsome Therapeutics reports record quarterly revenue - Investing.com
Axsome Therapeutics stock hits 52-week high at $98.61 - Investing.com India
Axsome shares rise as Guggenheim lifts target to $135 By Investing.com - Investing.com UK
Axsome Therapeutics Q3 Earnings: Stay For Near Term Catalysts, Then Sell (AXSM) - Seeking Alpha
Axsome Therapeutics (NASDAQ:AXSM) Reaches New 52-Week HighShould You Buy? - MarketBeat
A Closer Look at 10 Analyst Recommendations For Axsome Therapeutics - Benzinga
Axsome Therapeutics Inc earnings beat by $0.04, revenue topped estimates - Investing.com
Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates - MSN
Axsome Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Axsome Therapeutics' (AXSM) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Truist maintains buy on Axsome with $150 target on strong Auvelity sales - Investing.com UK
(AXSM) Proactive Strategies - Stock Traders Daily
Privium Fund Management B.V. Grows Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock Position Decreased by Lindbrook Capital LLC - MarketBeat
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024 - GlobeNewswire
Axsome Therapeutics to Present Breakthrough CNS Data Across 3 Major Disorders at NEI 2024 | AXSM Stock News - StockTitan
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Axsome Therapeutics (AXSM) to Release Earnings on Tuesday - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Position Trimmed by abrdn plc - MarketBeat
Assenagon Asset Management S.A. Lowers Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Analysts Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) Target Price at $124.64 - MarketBeat
(AXSM) Trading Advice - Stock Traders Daily
Upcoming Opportunities in Hypersomnia Therapeutics Market: - openPR
Axsome Therapeutics' (NASDAQ:AXSM) investors will be pleased with their impressive 257% return over the last five years - Simply Wall St
Major Depressive Disorder Market Expected to Experience Major Growth by 2034, According to DelveInsight | Takeda, Otsuka Pharma, AbbVie, SAGE Therapeutics, Forest Laboratories, Axsome Therapeutics - The Globe and Mail
Major Depressive Disorder Market Expected to Experience Major - openPR
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024 - The Manila Times
Axsome Therapeutics Presents Data from Multiple Programs - GlobeNewswire
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Axsome Therapeutics Inc Stock (AXSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Saad Mark E | Director |
Sep 11 '24 |
Option Exercise |
3.67 |
11,016 |
40,429 |
21,018 |
| Saad Mark E | Director |
Sep 11 '24 |
Sale |
91.31 |
11,016 |
1,005,871 |
10,002 |
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):